This study, for the first time, investigated the role of miR-556-5p/NLRP3 axis in regulating cisplatin-resistance in NSCLC, which broadened our knowledge in this field and provide alternative treatment strategies for NSCLC treatment in clinic. Here, NLRP3 is linked to non-small cell lung carcinoma.